Hutson Compares Avelumab for PD-L1 Positive Versus PD-L1 Negative Bladder Cancer
New Protocol for Advanced Kidney Cancer Involving Drug Combo of Avelumab and Axitinib - Thailand Medical News
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial - ESMO Open
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial - Journal of Thoracic Oncology
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study - The Lancet Oncology
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Nature Medicine
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study -
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial - European Urology
Cancers | Free Full-Text | The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials | HTML
Select clinical trials evaluating avelumab in combination with other... | Download Table
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - Annals of Oncology
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Avelumab Maintenance Therapy Shows Favorable Results After Frontline Chemotherapy in Bladder Cancer
Avelumab timeline from discovery to Merck-Pfizer Alliance, breakthrough... | Download Scientific Diagram
![PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/63896bbe64c237acb7d4260c2e84ab3aa4969933/29-Table2-1.png "PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar")
PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Select clinical trials evaluating avelumab in combination with other... | Download Table
Cancer immunotherapies targeting the PD-1 signaling pathway | Journal of Biomedical Science | Full Text
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer - Cancer Treatment Reviews
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma | NEJM
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma - Kazandjian - 2021 - The Oncologist - Wiley Online Library
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews
